Filing Flows › Comparisons › PRTA vs MCRB
Prothena Corp Public vs Seres Therapeutics: PRTA and MCRB compared
Prothena Corp Public is the larger company: $620K of revenue in its latest quarter (Q3 2026) against $593K for Seres Therapeutics (Q3 2026). Seres Therapeutics is growing faster (+69% against -74% a year earlier).
Where the money goes: PRTA and MCRB
Prothena Corp Public (PRTA) · Q3 2026
Prothena Corp Public, Q3 2026: revenue $620K (-74% year over year), net loss $16.5M, operating cash flow −$12.0M. The chart follows the revenue to costs, profit and cash.
Seres Therapeutics (MCRB) · Q3 2026
Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.
| Prothena Corp Public (PRTA) | Seres Therapeutics (MCRB) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $620K | $593K |
| Revenue growth, Y/Y | -74% | +69% |
| Operating margin | n/m | n/m |
| Net earnings | −$16.5M | −$16.3M |
| Operating cash flow | −$12.0M | −$10.5M |
Questions
Which is bigger, Prothena Corp Public or Seres Therapeutics?
Prothena Corp Public is the larger company: $620K of revenue in its latest quarter (Q3 2026) against $593K for Seres Therapeutics (Q3 2026).
Is Prothena Corp Public or Seres Therapeutics growing faster?
Seres Therapeutics is growing faster (+69% against -74% a year earlier).
More: Prothena Corp Public earnings · how Prothena Corp Public makes money · Seres Therapeutics earnings · how Seres Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.